MediWound Ltd. announced that Chief Executive Officer, Gal Cohen, has decided to step down after serving as the Company's CEO for more than 12 years. Mr. Cohen will end his term by the end of May 2019 and during this period, continue to support the Company's transition and ongoing strategic process. Sharon Malka, the Company's Chief Financial Officer and Chief Operations Officer, will be appointed CEO, and Stephen T. Wills, the Company's Chairman of the Board of Directors, will serve as Active Chairman.

Sharon Malka, 46, will assume the role of CEO after serving as the Company's Chief Financial & Operations Officer for the past 12 years. Prior to joining MediWound, Mr. Malka held various senior finance roles, including, as a co-founder and partner at Variance Economic Consulting, a full-service financial consulting firm, and as a senior manager at the Israeli member firm of PricewaterhouseCoopers (PwC). Mr. Stephen T. Wills, MediWound's Chairman, will serve as Active Chairman of the Company and continue to lead the ongoing strategic process, which is in advanced stages.

As the current Chief Financial Officer and Chief Operating Officer of Palatin Technologies Inc., and as the former Executive Chairman and CEO of Derma Sciences, Mr. Wills has vast experience in leading strategic transactions and licensing agreements, including the acquisition of Derma Sciences Inc. by Integra Life Sciences.